CARMIEL, Israel--(BUSINESS WIRE)--Protalix BioTherapeutics, Inc. (Amex: PLX), today announced it has been awarded a grant of up to approximately $4 million by the Office of the Chief Scientist (OCS) of Israel’s Ministry of Industry and Trade. The OCS has awarded this grant to the Company for the advancement of its clinical and preclinical drug development programs.
